Half Year 2022 Cosmo Pharmaceuticals NV Earnings Call Transcript
Good afternoon, everyone, and thank you very much for joining our half year results presentation. Let me walk you through our slides very quickly.
And let me just, first of all, remind you of who we are and what we do. So we consider ourselves a pharmaceutical company that develops and manufacture innovative products in the field of Gastroenterology, Health Tech and Dermatology. In gastroenterology, we cover gastrointestinal diseases, such as inflammatory bowel disease, colorectal cancer, irritable bowel syndrome in the diarrhea version and infectious diseases.
In Health Tech, we cover artificial intelligence applications in endoscopy, we have a device that's currently being distributed by Medtronic was a task of helping detecting lesions during colonoscopy, we have further applications underway. In Dermatology, we have the revolutionary acne drug that has just been launched in the U.S. market, and we are stepping into the Phase III for a drug on androgenetic alopecia.
Our business model is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
